logo-loader
viewBioCardia

BioCardia 'validated' by biopharma giant AstraZeneca in exclusive development agreement

BioCardia Inc (OTCMKTS:BCDA) CEO Peter Altman tells Proactive Investors the biotechnology company has signed an extension to a 2017 development agreement with pharma giant AstraZeneca PLC (NYSE:AZN) to use the firm's Helix biotherapeutic delivery catheter system.

Altman says as part of the agreement, BioCardia will have the potential to advance Helix into clinical development with the UK-based company.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Matinas BioPharma to begin dosing HIV patients with...

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive it will begin a Part 2 study of MAT2203 for the treatment of HIV patients with cryptococcal meningitis. Jabbour explains how the New Jersey-based company will begin dosing its first patient in the...

1 hour, 48 minutes ago

2 min read